Summary of Study ST003362
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002088. The data can be accessed directly via it's Project DOI: 10.21228/M8QJ9B This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST003362 |
| Study Title | Metabolomics analysis of Glioblastoma (GBM) cell line U251 labeled by 13C-glutamine after treatment with pimozide |
| Study Summary | Glioblastoma (GBM) cell line U251 was treated with antipsychotic drug pimozide (3 uM) for 24 hr, and then labeled with 13C-glutamine (2 mM) for 1 hr. Cells were collected and extracted for metabolites and analyzed by LC-MS. Our data showed that pimozide treatment significantly increased 13C-labeled glutamine uptake and subsequent consumption, including anaplerosis of metabolites for tricarboxylic acid (TCA) cycle and de novo fatty acid synthesis derived from glutamine-mediated reductive carboxylation process. |
| Institute | Ohio State University |
| Last Name | Guo |
| First Name | Deliang |
| Address | Department of Radiation Oncology, Ohio State Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, and College of Medicine at The Ohio State University, Columbus, OH 43210, USA. |
| deliang.guo@osumc.edu | |
| Phone | 6143663774 |
| Submit Date | 2024-07-29 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML |
| Analysis Type Detail | LC-MS |
| Release Date | 2024-08-05 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Collection:
| Collection ID: | CO003476 |
| Collection Summary: | 1) For labelled Group: 3 million U251 cells were seeded in a 15-cm dish for 24 hr, then treated with/without the drug (Pimozide: 3 µM) in a fresh medium containing 1% FBS, 5 mM glucose, 4 mM glutamine for another 24 hr. After drug treatment, cells were deprived for 1 hr with a serum-free medium containing 5 mM glucose, 0 mM glutamine, and 1 mM pyruvate. 2 mM 13C(U)-glutamine was added to the media and incubated for 1 hr. The cells were washed twice with cold PBS and quenched with cold acetonitrile and ultrapure water (4:3, v:v) for 5 min, and metabolites were extracted for subsequent LC-MS analysis. Long chain fatty acid Control: U251 cells without pimozide treatment. Long chain fatty acid Pimozide: U251 cells with pimozide treatment. |
| Sample Type: | Glioma cells |
